Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 2
2012 2
2015 2
2016 2
2017 1
2018 4
2019 5
2020 3
Text availability
Article attribute
Article type
Publication date

Search Results

14 results
Results by year
Filters applied: in the last 5 years. Clear all
Page 1
Outcome of Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis Associated With Deletion of 17p.
Wong SW, et al. Clin Lymphoma Myeloma Leuk 2018. Among authors: Landau HJ. PMID 30104177 Free article.
INTRODUCTION: Deletion 17p (del 17p) portends a poor prognosis in myeloma, but its significance in light-chain amyloidosis is unknown. PATIENTS AND METHODS: We identified patients with light-chain amyloidosis and del 17p at diagnosis, and analyzed presenting characteristics, treatments, and clinical outcomes. ...
INTRODUCTION: Deletion 17p (del 17p) portends a poor prognosis in myeloma, but its significance in light-chain amyloidosis is unknown …
Early Detection of Multiorgan Light-Chain Amyloidosis by Whole-Body (18)F-Florbetapir PET/CT.
Ehman EC, et al. J Nucl Med 2019. Among authors: Landau H. PMID 30954943 Free PMC article.
Immunoglobulin light-chain (AL) amyloidosis affects multiple systemic organs. However, determination of the precise extent of organ involvement remains challenging. ...Methods: This prospective study included 40 subjects with biopsy-proven AL amyloidosis including active AL amyloidosis (n = 30) or AL amyloidosis in hematologic remission for more than 1 y (n = 10). ...
Immunoglobulin light-chain (AL) amyloidosis affects multiple systemic organs. However, determination of the precise extent of organ i …
Light Chain Amyloidosis: Patient Experience Survey from the Amyloidosis Research Consortium.
Lousada I, et al. Adv Ther 2015. Among authors: Landau H. PMID 26498944 Free PMC article.
METHODS: Patients with amyloidosis, family members, and caregivers were invited to participate in an online 16-question survey (available from January 29 to February 5, 2015). ...AL amyloidosis was the most common diagnosis. For 37.1% of respondents, the diagnosis of amyloidosis was not established until ≥ 1 year after the onset of initial symptoms. ...
METHODS: Patients with amyloidosis, family members, and caregivers were invited to participate in an online 16-question survey (avail …
Modified High-Dose Melphalan and Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis.
Nguyen VP, et al. Biol Blood Marrow Transplant 2018. Among authors: Landau H. PMID 29933072 Free article.
High-dose melphalan and autologous stem cell transplantation (HDM/SCT) have been used in patients with immunoglobulin light chain (AL) amyloidosis for over 2 decades now with durable responses, prolonged survival, and decreasing treatment-related mortality. ...With the advent of novel therapeutic agents such as proteasome inhibitors, immunomodulatory agents, and monoclonal antibodies for the treatment of AL amyloidosis, it is imperative to understand the long-term effects of mHDM/SCT. ...
High-dose melphalan and autologous stem cell transplantation (HDM/SCT) have been used in patients with immunoglobulin light chain (AL) am
Quantitative [(18)F]florbetapir PET/CT may identify lung involvement in patients with systemic AL amyloidosis.
Khor YM, et al. Eur J Nucl Med Mol Imaging 2019. Among authors: Landau H. PMID 31807884
The aim of this study is to determine quantitative [(18)F]florbetapir pulmonary kinetics to identify pulmonary involvement in individuals with systemic AL amyloidosis. METHODS: We prospectively enrolled 58 subjects with biopsy-proven AL amyloidosis and 9 control subjects (5 without amyloidosis and 4 with ATTR cardiac amyloidosis). ...
The aim of this study is to determine quantitative [(18)F]florbetapir pulmonary kinetics to identify pulmonary involvement in individuals wi …
Prognostic and Added Value of Two-Dimensional Global Longitudinal Strain for Prediction of Survival in Patients with Light Chain Amyloidosis Undergoing Autologous Hematopoietic Cell Transplantation.
Pun SC, et al. J Am Soc Echocardiogr 2018. Among authors: Landau HJ. PMID 29111123 Free PMC article.
BACKGROUND: Autologous hematopoietic cell transplantation (HCT) is a first-line therapy for prolonging survival in patients with light-chain (AL) amyloidosis. ...METHODS: Eighty-two patients with newly diagnosed AL amyloidosis who underwent upfront HCT between January 2007 and April 2014 were included in the study. ...
BACKGROUND: Autologous hematopoietic cell transplantation (HCT) is a first-line therapy for prolonging survival in patients with light-chain …
First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction.
Gertz MA, et al. J Clin Oncol 2016 - Clinical Trial. Among authors: Landau H. PMID 26858336 Free PMC article.
PURPOSE: Light chain (AL) amyloidosis is caused by the accumulation of misfolded proteins, which induces the dysfunction of vital organs. ...Antibody therapy targeting misfolded proteins is a potential new therapy for the management of AL amyloidosis....
PURPOSE: Light chain (AL) amyloidosis is caused by the accumulation of misfolded proteins, which induces the dysfunction of vital org …
14 results
Jump to page
Feedback